Baidu
map

J Clin Endocrinol Metab:左旋甲状腺素治疗不会影响亚临床甲状腺功能减退症老年患者的血红蛋白水平

2022-07-19 MedSci原创 MedSci原创

亚临床甲状腺功能障碍和贫血是常见的疾病,而且随着年龄的增长,两者的发病率都在增加。

亚临床甲状腺功能障碍和贫血是常见的疾病,而且随着年龄的增长,两者的发病率都在增加。近日,发表于J Clin Endocrinol Metab的一项研究评估了左旋甲状腺素治疗是否会导致亚临床甲状腺功能减退的老年人的血红蛋白水平上升。

在这项预先计划的2项随机对照试验中,研究人员综合分析了 669 名 65 岁及以上亚临床甲状腺功能减退症的社区居民,将其随机分配到左旋甲状腺素或安慰剂治疗。左旋甲状腺素的剂量是定期滴定的,目的是使促甲状腺激素(TSH)水平在参考范围内,安慰剂组则是模拟滴定。主要的结果测量是 12 个月后血红蛋白水平的变化。

结果,安慰剂组 337 名参与者,左旋甲状腺素组 332 名参与者,中位年龄为 75 岁(范围,65-97),平均基线血红蛋白为13.8 ± 1.3 g/dL。尽管与安慰剂相比,左旋甲状腺素治疗导致12个月后TSH从基线下降,但左旋甲状腺素组和安慰剂组之间的血红蛋白水平变化没有差异(-0.03 g/dL [95% CI, -0.16 to 0.11])。在包括性别、年龄或TSH水平的分层分析中也发现类似的结果。在基线时有贫血的 69 名参与者中,12 个月后血红蛋白水平的变化没有发现差异(-0.33 g/dL [95% CI, -0.87 to 0.21])。

 

综上所述,该研究结果表明,在65岁及以上的亚临床甲状腺功能减退症患者中,无论是否存在贫血,用左旋甲状腺素治疗都不会导致血红蛋白水平的上升。

原始出处:

Robert S Du Puy, et al., No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism: Pooled Results From 2 Randomized Controlled Trials. J Clin Endocrinol Metab. 2022 May 17;107(6):e2339-e2347. doi: 10.1210/clinem/dgac106.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797441, encodeId=98a71e97441f6, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Nov 19 14:58:33 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888450, encodeId=7871188845012, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Dec 28 02:58:33 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897037, encodeId=41e1189e037b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 20 06:58:33 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233734, encodeId=1a9a1233e3457, content=新的研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38e15623542, createdName=ms5000001440725634, createdTime=Wed Jul 20 23:14:59 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456964, encodeId=66d3145696465, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538194, encodeId=65ec153819458, content=<a href='/topic/show?id=6a032421985' target=_blank style='color:#2F92EE;'>#亚临床甲状腺功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24219, encryptionId=6a032421985, topicName=亚临床甲状腺功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c34212938139, createdName=bsmagic9136, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247320, encodeId=9cf4124e3204f, content=大家一般关心疾病,但是亚临床更重要,这是疾病防控方向的前移,各类疾病都是这样。如亚临床甲减,亚临床心肌损伤,亚临床心衰等, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jingjing, createdTime=Mon Jul 11 23:58:33 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797441, encodeId=98a71e97441f6, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Nov 19 14:58:33 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888450, encodeId=7871188845012, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Dec 28 02:58:33 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897037, encodeId=41e1189e037b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 20 06:58:33 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233734, encodeId=1a9a1233e3457, content=新的研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38e15623542, createdName=ms5000001440725634, createdTime=Wed Jul 20 23:14:59 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456964, encodeId=66d3145696465, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538194, encodeId=65ec153819458, content=<a href='/topic/show?id=6a032421985' target=_blank style='color:#2F92EE;'>#亚临床甲状腺功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24219, encryptionId=6a032421985, topicName=亚临床甲状腺功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c34212938139, createdName=bsmagic9136, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247320, encodeId=9cf4124e3204f, content=大家一般关心疾病,但是亚临床更重要,这是疾病防控方向的前移,各类疾病都是这样。如亚临床甲减,亚临床心肌损伤,亚临床心衰等, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jingjing, createdTime=Mon Jul 11 23:58:33 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-12-28 guojianrong
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797441, encodeId=98a71e97441f6, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Nov 19 14:58:33 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888450, encodeId=7871188845012, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Dec 28 02:58:33 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897037, encodeId=41e1189e037b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 20 06:58:33 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233734, encodeId=1a9a1233e3457, content=新的研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38e15623542, createdName=ms5000001440725634, createdTime=Wed Jul 20 23:14:59 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456964, encodeId=66d3145696465, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538194, encodeId=65ec153819458, content=<a href='/topic/show?id=6a032421985' target=_blank style='color:#2F92EE;'>#亚临床甲状腺功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24219, encryptionId=6a032421985, topicName=亚临床甲状腺功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c34212938139, createdName=bsmagic9136, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247320, encodeId=9cf4124e3204f, content=大家一般关心疾病,但是亚临床更重要,这是疾病防控方向的前移,各类疾病都是这样。如亚临床甲减,亚临床心肌损伤,亚临床心衰等, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jingjing, createdTime=Mon Jul 11 23:58:33 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-10-20 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797441, encodeId=98a71e97441f6, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Nov 19 14:58:33 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888450, encodeId=7871188845012, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Dec 28 02:58:33 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897037, encodeId=41e1189e037b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 20 06:58:33 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233734, encodeId=1a9a1233e3457, content=新的研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38e15623542, createdName=ms5000001440725634, createdTime=Wed Jul 20 23:14:59 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456964, encodeId=66d3145696465, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538194, encodeId=65ec153819458, content=<a href='/topic/show?id=6a032421985' target=_blank style='color:#2F92EE;'>#亚临床甲状腺功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24219, encryptionId=6a032421985, topicName=亚临床甲状腺功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c34212938139, createdName=bsmagic9136, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247320, encodeId=9cf4124e3204f, content=大家一般关心疾病,但是亚临床更重要,这是疾病防控方向的前移,各类疾病都是这样。如亚临床甲减,亚临床心肌损伤,亚临床心衰等, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jingjing, createdTime=Mon Jul 11 23:58:33 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-20 ms5000001440725634

    新的研究方向

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1797441, encodeId=98a71e97441f6, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Nov 19 14:58:33 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888450, encodeId=7871188845012, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Dec 28 02:58:33 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897037, encodeId=41e1189e037b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 20 06:58:33 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233734, encodeId=1a9a1233e3457, content=新的研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38e15623542, createdName=ms5000001440725634, createdTime=Wed Jul 20 23:14:59 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456964, encodeId=66d3145696465, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538194, encodeId=65ec153819458, content=<a href='/topic/show?id=6a032421985' target=_blank style='color:#2F92EE;'>#亚临床甲状腺功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24219, encryptionId=6a032421985, topicName=亚临床甲状腺功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c34212938139, createdName=bsmagic9136, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247320, encodeId=9cf4124e3204f, content=大家一般关心疾病,但是亚临床更重要,这是疾病防控方向的前移,各类疾病都是这样。如亚临床甲减,亚临床心肌损伤,亚临床心衰等, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jingjing, createdTime=Mon Jul 11 23:58:33 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1797441, encodeId=98a71e97441f6, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Nov 19 14:58:33 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888450, encodeId=7871188845012, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Dec 28 02:58:33 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897037, encodeId=41e1189e037b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 20 06:58:33 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233734, encodeId=1a9a1233e3457, content=新的研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38e15623542, createdName=ms5000001440725634, createdTime=Wed Jul 20 23:14:59 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456964, encodeId=66d3145696465, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538194, encodeId=65ec153819458, content=<a href='/topic/show?id=6a032421985' target=_blank style='color:#2F92EE;'>#亚临床甲状腺功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24219, encryptionId=6a032421985, topicName=亚临床甲状腺功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c34212938139, createdName=bsmagic9136, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247320, encodeId=9cf4124e3204f, content=大家一般关心疾病,但是亚临床更重要,这是疾病防控方向的前移,各类疾病都是这样。如亚临床甲减,亚临床心肌损伤,亚临床心衰等, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jingjing, createdTime=Mon Jul 11 23:58:33 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1797441, encodeId=98a71e97441f6, content=<a href='/topic/show?id=b84c22894e2' target=_blank style='color:#2F92EE;'>#临床甲状腺功能减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22894, encryptionId=b84c22894e2, topicName=临床甲状腺功能减退)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6fc262, createdName=zhangmingxiang, createdTime=Sat Nov 19 14:58:33 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888450, encodeId=7871188845012, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Dec 28 02:58:33 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897037, encodeId=41e1189e037b1, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Oct 20 06:58:33 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233734, encodeId=1a9a1233e3457, content=新的研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38e15623542, createdName=ms5000001440725634, createdTime=Wed Jul 20 23:14:59 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456964, encodeId=66d3145696465, content=<a href='/topic/show?id=864d48113ea' target=_blank style='color:#2F92EE;'>#左旋甲状腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48113, encryptionId=864d48113ea, topicName=左旋甲状腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24a45820141, createdName=liuhuangbo, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538194, encodeId=65ec153819458, content=<a href='/topic/show?id=6a032421985' target=_blank style='color:#2F92EE;'>#亚临床甲状腺功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24219, encryptionId=6a032421985, topicName=亚临床甲状腺功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c34212938139, createdName=bsmagic9136, createdTime=Wed Jul 13 11:58:33 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247320, encodeId=9cf4124e3204f, content=大家一般关心疾病,但是亚临床更重要,这是疾病防控方向的前移,各类疾病都是这样。如亚临床甲减,亚临床心肌损伤,亚临床心衰等, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jingjing, createdTime=Mon Jul 11 23:58:33 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-11 jingjing

    大家一般关心疾病,但是亚临床更重要,这是疾病防控方向的前移,各类疾病都是这样。如亚临床甲减,亚临床心肌损伤,亚临床心衰等

    0

相关资讯

CJASN:罗沙司他可有效纠正非透析依赖性CKD患者的贫血,且不增加心血管事件风险

罗沙司他可有效升高非透析依赖性CKD患者的血红蛋白水平,纠正贫血,同时降低输血需求,而且不增加MACE风险

Circulation:Vericiguat对射血分数降低心衰患者血红蛋白和临床结局的影响

Vericiguat治疗后贫血很常见,较低的血红蛋白与较高的临床事件发生频率相关。尽管Vericiguat治疗16周时血红蛋白适度降低,但这种效果没有进一步发展。

血红蛋白156g/L,竟然还缺铁?

血常规岗位,一张验单引起了我的注意,该患者红细胞增高、血红蛋白增高,但是MCV、MCH、MCHC都是减低

JCEM:左甲状腺素对亚临床甲状腺功能减退症老年人血红蛋白没有影响

对于65岁及以上的亚临床甲状腺功能减退症患者,无论是否存在贫血,左甲状腺素治疗都不会导致血红蛋白水平升高。

指标解读:检验指标临床解读(18)血红蛋白异常性贫血

HbF轻度增高可见于:50%的轻型β-珠蛋白生成障碍性贫血、再生障碍性贫血(AA)、阵发性睡眠性血红蛋白尿(PNH)、真性红细胞增多症、铁粒幼细胞贫血、白血病等。

美国FDA扩大镰状细胞病药物Oxbryta的适应症

FDA 扩大了 Oxbryta(voxelotor)的适应症,允许其治疗 4 至 12 岁以下儿童的镰状细胞病(SCD)。

Baidu
map
Baidu
map
Baidu
map